目的:在骨健康诊所的背景下,分析不同专业的骨质疏松症药物处方趋势。
背景:骨质疏松影响了美国超过1000万成年人,对患者和医疗系统造成重大损失。尽管筛查方法和治疗方法正在改善,这种疾病仍然未被诊断和治疗不足。这项研究旨在评估科室专业中骨质疏松症药物的处方趋势,以描述骨骼健康诊所的益处。
方法:回顾性数据收集确定并分析了宾夕法尼亚州立大学卫生系统规定的以下骨质疏松症药物之一的患者:双膦酸盐,denosumab,romosozumab,特立帕肽,abaloparatide,或者雷洛昔芬.日期范围:2016年4月18日至2021年4月14日。数据收集确定了各种医学专业的骨质疏松症药物处方的专业起源(例如,骨科,家庭医学,和内科)。
结果:对平均年龄为68岁的患者开具了10,736份处方单。非西班牙裔高加索患者接受了88.6%的处方,其次是亚洲人(3.4%)和非洲裔美国人(2.2%)。女性患者占所有处方的87.8%。两个骨科提供者下的骨健康诊所开了3,619张处方,平均每个提供者每年有361.9张处方-这是各专业中最高的比例。诊所处方占所有专科处方的33.7%。骨科手术开出了最多的denosumab,romosozumab,特立帕肽,和阿巴罗帕拉肽处方,与其他专科相比,男性骨质疏松症患者数量最多(15.6%),因此开处方最多的男性处方(578)。
结论:建立致力于骨质疏松症管理的骨骼健康诊所会导致每个提供者的处方率明显更高,与其他专业相比,合成代谢疗法的利用率更高,更多的男性患者正在接受治疗,这是骨质疏松症中经常被忽视的人群。
OBJECTIVE: To analyze osteoporosis medication prescribing trends across specialties in the context of a Bone Health Clinic.
BACKGROUND: Osteoporosis affects over 10 million adults in the US, taking a significant toll on patients and the healthcare system. Although screening methods and treatments are improving, the disease remains underdiagnosed and undertreated. This study aims to evaluate the prescribing trends of osteoporosis medication among department specialties to delineate the benefits of a bone health clinic.
METHODS: Retrospective data collection identified and analyzed patients within the Penn State Health system prescribed one of the following osteoporosis medications: Bisphosphonate, denosumab, romosozumab,
teriparatide, abaloparatide, or raloxifene. Date range: 4/18/2016 to 4/14/2021. Data collection identified the specialty origin of prescriptions for osteoporosis medications across various medical specialties (e.g., orthopaedics, family medicine, and internal medicine).
RESULTS: 10,736 prescription orders were issued to patients with an average age of 68 years. Non-Hispanic Caucasian patients received 88.6% of prescriptions, followed by Asian (3.4%) and African American (2.2%). Female patients accounted for 87.8% of all prescriptions. The Bone Health Clinic under two orthopaedic providers wrote 3,619 prescriptions, averaging 361.9 prescriptions per provider per year-marking the highest rate among specialties. The clinic prescriptions constituted 33.7% of all prescriptions across specialties. Orthopaedic surgery prescribed the most denosumab, romosozumab,
teriparatide, and abaloparatide prescriptions, and had the highest number of male osteoporosis patients compared to other specialties (15.6%), consequently prescribing the most male prescriptions (578).
CONCLUSIONS: Establishing a bone health clinic dedicated to osteoporosis management leads to significantly higher prescription rates per provider, increased utilization of anabolic therapies compared to other specialties, and more male patients being treated-an often-neglected population in osteoporosis.